The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
Abstract
Background Oral anticoagulation therapy reduces risk of vascular events in patients with atrial fibrillation. However, long-term monitoring is necessary and many patients cannot achieve optimum anticoagulation. We assessed whether clopidogrel plus aspirin was non-inferior to oral anticoagulation therapy for prevention of vascular events.Methods Patients were enrolled if they had atrial fibrillation plus one or more risk factor for stroke, and were randomly allocated to receive oral anticoagulation therapy (target international normalised ratio of 2.0-3.0; n=3371) or clopidogrel (75 mg per day) plus aspirin (75-100 mg per day recommended; n=3335). Outcome events were adjudicated by a blinded committee. Primary outcome was first occurrence of stroke, non-CNS systemic embolus, myocardial infarction, or vascular death. Analyses were by intention-to-treat. This study is registered with ClinicalTrials.gov, number NCT00243178.Results The study was stopped early because of clear evidence of superiority of oral anticoagulation therapy. There were 165 primary events in patients on oral anticoagulation therapy (annual risk 3.93%) and 234 in those on clopidogrel plus aspirin (annual risk 5.60%; relative risk 1.44 (1.18-1.76; p=0.0003). Patients on oral anticoagulation therapy who were already receiving this treatment at study entry had a trend towards a greater reduction in vascular events (relative risk 1.50, 95% CI 1.19-1.89) and a significantly (p=0.03 for interaction) lower risk of major bleeding with oral anticoagulation therapy (1.30; 0.94-1.79) than patients not on this treatment at study entry (1.27, 0.85-1.89 and 0.59, 0.32-1.08, respectively).Conclusion Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoagulation therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“VKA therapy prevents stroke, non-central nervous system embolus, myocardial infarction, and vascular death better than single or dual antiplatelet therapy with aspirin and clopidogrel (annual risk of 5.6% for aspirin and clopidogrel vs. 3.9% with VKA therapy).431”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [431]
Citations
Cites
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention
Steinhubl, S. R., Berger, P. B., Mann, J. T., Fry, E. T. A., DeLago, A. J., Wilmer, C. I., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,071
Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.13.1449 · Cited by 2,602
Sabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Théroux, P., Claeys, M. J., Cools, F. J. S., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,912
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H. I., Ansell, J., & Deykin, D. (2001) · CHEST Journal · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,813
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation
Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-7-199910050-00003 · Cited by 1,636
ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary
Fuster, V., Rydén, L., ASINGER, R. W., Cannom, D. S., Crijns, H. J. G. M., Frye, R. L., Halperin, J. L., Kay, G. N., Klein, W. W., Lévy, S., et al. (2001) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01587-x · Cited by 1,362
Atrial Fibrillation: A Major Contributor to Stroke in the Elderly: The Framingham Study
Wolf, P. A. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370090041008 · Cited by 1,108
Cited by
Sorted by citations
Items 801–900 of 1,000
Practice Implications of the Atrial Fibrillation Guidelines
Curtis, A. B. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.01.338 · Cited by 11
“The basis for this recommendation was the results from the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W) and Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation (ACTIVE A) trials.(28,29) The results of the ACTIVE W trial indicate that oral an…”
ResultTransient atrial fibrillation complicating acute myocardial infarction: A nuisance or a nemesis?
Lam, C.-C., Tse, H., & Siu, C. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-11-0807 · Cited by 11
Ruiz-Nodar, J. M., Marín, F. R., & Lip, G. Y. H. (2012) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.07.018 · Cited by 10
Antiplatelet therapy in secondary stroke prevention – state of the art
Diener, H., Weimar, C., & Weber, R. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01163.x · Cited by 12
Dinh, T., Baur, L. H. B., Pisters, R., Otto Kamp, B., Verheugt, F. W. A., Smeets, J. L. R. M., Cheriex, E. C., Lindeboom, J.-E., Heesen, W. F., Tieleman, R. G., et al. (2014) · Heart · doi:10.1136/heartjnl-2013-305017 · Cited by 11
Barbieri, L., Verdoia, M., Schaffer, A., Suryapranata, H., & Luca, G. D. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6692-z · Cited by 11
Wong, C. (2016) · Hong Kong Medical Journal · doi:10.12809/hkmj154803 · Cited by 11
Lee, J., Joung, B., Cha, M., Lee, J. H., Lim, W., Kim, T., Shin, S. Y., Uhm, J., Lim, H. E., Kim, J., et al. (2018) · Korean Journal of Medicine · doi:10.3904/kjm.2018.93.2.87.e1 · Cited by 11
Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified
Andrade, J. G., Deyell, M. W., Wong, G. C., & Macle, L. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.08.028 · Cited by 11
Song, C., Bi, L., Zhao, J., Wang, X., Li, W., Yang, F., & Jiang, W. (2021) · International Journal of Medical Sciences · doi:10.7150/ijms.52752 · Cited by 11
“However, aspirin alone is significantly less efficacious than warfarin [10, 29, 30], and aspirin plus clopidogrel has also been verified to be inferior to warfarin in both efficacy and safety [31].”
BackgroundWang, W., Huang, Q., Pan, D., Zheng, W., & Zheng, S. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.03.047 · Cited by 13
SCHRICKEL, J. W., Linhart, M., Bänsch, D., Thomas, D., & Nickenig, G. (2015) · Clinical Research in Cardiology · doi:10.1007/s00392-015-0933-1 · Cited by 11
Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Hankey, G. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328334e67b · Cited by 11
Antithrombotic Therapy in Cardiac Embolism
Cervera, Á., & Chamorro, Á. (2010) · Current Cardiology Reviews · doi:10.2174/157340310791658749 · Cited by 11
Managing anticoagulation for atrial fibrillation: current issues and future strategies
Camm, A. J. (2012) · Journal of Internal Medicine · doi:10.1111/joim.12001 · Cited by 11
Filling the gap between science & clinical practice: Prevention of stroke recurrence
Russolillo, A., Minno, M. N. D. D., Tufano, A., Prisco, D., & Minno, G. D. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.08.012 · Cited by 11
Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation
Zoppellaro, G., Granziera, S., Jose, S. P., Denas, G., Bracco, A., Iliceto, S., & Pengo, V. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1024222 · Cited by 11
“However, in the past decade, many studies and meta-analyses [17] showed that anticoagulants are significantly more effective than aspirin [18], aspirin + clopidogrel [19] and aspirin + fixed low dose of warfarin [9,20] at stroke prevention.”
BackgroundKhattab, A. A., Gloekler, S., Sprecher, B., Shakir, S., Guérios, Ê. E., Stortecky, S., O'Sullivan, C. J., Nietlispach, F., Moschovitis, A., Pilgrim, T., et al. (2014) · Open Heart · doi:10.1136/openhrt-2013-000014 · Cited by 11
Staudacher, D. L., Kaiser, M., Hehrlein, C., Bode, C., & Ahrens, I. (2015) · PLoS ONE · doi:10.1371/journal.pone.0140101 · Cited by 11
Oral Direct Factor Xa Inhibitors, with Special Emphasis on Rivaroxaban
Mousa, S. A. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-803-4_6 · Cited by 11
Noelck, N. J., Papak, J., Freeman, M., Paynter, R. A., Low, A., Motu’apuaka, M. L., Kondo, K. K., & Kansagara, D. L. (2016) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.115.002539 · Cited by 11
Drug eluting stents in Belgium: health technology assessment
Neyt, M., Brabandt, H. V., Devriese, S., Mahieu, J., Ridder, A. D., Graeve, D. D., & Laet, C. E. D. H. D. (2007) · Cited by 11
How I use anticoagulation in atrial fibrillation
Steinberg, B. A. (2016) · Blood · doi:10.1182/blood-2016-07-693614 · Cited by 11
Koyama, T., Otsuka, Y., Kawahara, M., Imoto, Y., Nakamura, K., Kodama, S., & Noguchi, H. (2017) · Clinical Case Reports · doi:10.1002/ccr3.933 · Cited by 11
Lakkireddy, D. (2017) · Journal of Atrial Fibrillation · doi:10.4022/jafib.1729 · Cited by 11
Melillo, E., Carbone, A., Rago, A., Papa, A. A., Onofrio, A. D., Nigro, G., Golino, P., & Russo, V. (2019) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000786 · Cited by 11
Hernández, J. M. D. L. T., Ferreiro, J. L., López‐Palop, R., Ojeda, S., Sánchez, D. M., y, P. A., Vicente, J. A. L., Diego‐Nieto, A., Amat-Santos, I. J., Tellería, M., et al. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.05.036 · Cited by 11
Khurshid, S. S., Chen, W., Singer, D. E., Atlas, S. J., Ashburner, J. M., Choi, J., Hur, C., Ellinor, P. T., McManus, D. D., Chhatwal, J., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020330 · Cited by 12
“7,19,20 We modeled the effect of antithrombotic therapy on stroke incidence and severity as a function of the presence or absence of AF.”
Rubboli, A. (2012) · 老年心脏病学杂志：英文版 · doi:10.3724/sp.j.1263.2011.00207 · Cited by 11
Antiplatelet Drugs for Ischemic Stroke Prevention
Leys, D., Balucani, C., & Cordonnier, C. (2009) · Cerebrovascular Diseases · doi:10.1159/000200449 · Cited by 11
Platelet adhesion in atrial fibrillation
Choudhury, A., Chung, I. K.-K., Blann, A. D., & Lip, G. Y. H. (2007) · Thrombosis Research · doi:10.1016/j.thromres.2006.12.008 · Cited by 11
Olivier, C. B., Fan, J., Askari, M., Mahaffey, K. W., Heidenreich, P. A., Perino, A. C., Leef, G. C., Ho, P. M., Harrington, R. A., & Turakhia, M. P. (2019) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.118.007604 · Cited by 11
Alexander, J. H., Lydon, E. J., Piccini, J. P., Viethen, T., Oldgren, J., Goodman, S. G., Steffel, J., Russo, A. M., Gelder, I. C. V., Ferdinand, K. C., et al. (2025) · JAMA Cardiology · doi:10.1001/jamacardio.2025.0277 · Cited by 10
Dabigatran efficacy‐safety assessment for stroke prevention in patients with atrial fibrillation
Eikelboom, J. W., QUINLAN, D. J., Connolly, S. J., Hart, R. G., & Yusuf, S. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04668.x · Cited by 10
New anticoagulants for the prevention of stroke in atrial fibrillation
Höchtl, T., & Huber, K. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00982.x · Cited by 10
Cardiological Aspects of Stroke Prevention
Fisher, M., & McAllister, M. (2015) · Circulation Journal · doi:10.1253/circj.cj-14-1342 · Cited by 11
Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation
Liew, A., Eikelboom, J. W., & O'Donnell, M. J. (2012) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283540857 · Cited by 10
“The addition of clopidogrel to aspirin further reduces the risk of stroke by 28%, but the combination is still less effective than warfarin, despite being associated with a similar rate of bleeding [6,7].”
BackgroundNew pharmacotherapy for stroke prevention in atrial fibrillation: Update 2010
Armaganijan, L., Eikelboom, J. W., Healey, J. S., & Morillo, C. A. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0084-8 · Cited by 9
Triple Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI: a Fading Role
Alexopoulos, D. K., Vlachakis, P. K., & Lekakis, J. P. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6730-5 · Cited by 10
“Of importance, DAPT is superior to OAC therapy for patients with AF and PCI for prevention of thrombosis of the stent, while OAC therapy is superior to treatment with DAPT for preventing thromboembolic events [4, 5].”
Cho, M. S., Kang, D., Oh, Y., Lee, C. H., Choi, E., Lee, J. H., Kwon, C. H., Park, G., Park, H. W., Park, K., et al. (2022) · American Heart Journal · doi:10.1016/j.ahj.2022.01.014 · Cited by 11
Bergman, D. L. (2011) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2011.00650.x · Cited by 11
Role of Antithrombotic Agents in Heart Failure
Cleland, J. G. F., Mumtaz, S., & Cecchini, L. (2012) · Current Cardiology Reports · doi:10.1007/s11886-012-0266-x · Cited by 10
“is superior to aspirin alone for patients with AF who were ineligible for treatment with warfarin [82, 83].”
BackgroundVKORC1 and CYP2C9 Genotype Variations in Relation to Warfarin Dosing in Korean Stroke Patients
Park, S. M., Lee, J., Chun, S. I., Lee, H. I., Kwon, S. U., Kang, D., & Kim, J. S. (2013) · Journal of Stroke · doi:10.5853/jos.2013.15.2.115 · Cited by 10
Is there a role for warfarin anymore?
Jacobson, A. K. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.541.3798556 · Cited by 10
Stacy, Z. A., & Richter, S. K. (2016) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029616634886 · Cited by 11
“This trial was terminated early due to clear superiority of oral anticoagulation therapy.(21) In the ACTIVE-A (Atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events)trial, 7554 patients with AF, who were at increased risk of stroke and not good candidates for VKA therapy, were randoml…”
MethodAtrial fibrillation and thromboembolic risk in Greece.
Korantzopoulos, P. G., Andrikopoulos, G. K., Vemmos, K. N., Goudevenos, J. A., & Vardas, P. E. (2012) · PubMed · Cited by 10
Zheng, H., Ouyang, S., Zhao, Y., Lü, K., Luo, S., & Xiao, H. (2017) · International Journal of General Medicine · doi:10.2147/ijgm.s128047 · Cited by 10
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial
Peterson, B. E., Bhatt, D. L., Steg, P. G., Oldgren, J., Mæng, M., Zeymer, U., Halvorsen, S., Hohnloser, S. H., Lip, G. Y. H., Kimura, T., et al. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2021.02.022 · Cited by 10
Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment.
(2017) · PubMed Central · Cited by 10
Zhou, X., Chen, Q., Fang, L., Wang, L., Chen, Y., Liang, D., Huang, W., & Xiao, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12030847 · Cited by 10
“DAPT is most commonly used in patients with contraindications to OACs [19].”
BackgroundAnticoagulation for Atrial Fibrillation: A Review of Current Literature and Views
Jin, C., Cui, C., Seplowe, M., Lee, K., Vegunta, R., Li, B., Frishman, W. H., & Iwai, S. (2022) · Cardiology in Review · doi:10.1097/crd.0000000000000489 · Cited by 10
Acute Management of Atrial Fibrillation
Beck, H., & See, V. Y. (2012) · Cardiology Clinics · doi:10.1016/j.ccl.2012.07.007 · Cited by 11
Warfarin: Impact on hemostasis after radial catheterization
Lippe, C. M., Reineck, E. A., Kunselman, A. R., & Gilchrist, I. C. (2014) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.25410 · Cited by 10
Improving the use of direct oral anticoagulants in atrial fibrillation
Minno, G. D., Russolillo, A., Gambacorta, C., Minno, A. D., & Prisco, D. (2013) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2013.01.021 · Cited by 10
“However, in head-to-head comparisons, intra-cerebral hemorrhages were quantitatively comparable in AF subjects on warfarin and in those on aspirin plus clopidogrel [2,3], and the superiority of warfarin in the prevention of thromboembolic events was constant throughout different CHADS2 scores [4].”
ResultOld and New Anticoagulant Agents for the Prevention and Treatment of Patients with Ischemic Stroke
Martí‐Fábregas, J., & Mateo, J. (2009) · Cerebrovascular Diseases · doi:10.1159/000200448 · Cited by 10
Thomas, G., & Lerman, B. B. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0188-x · Cited by 10
Rubboli, A., Bolognese, L., Pasquale, G. D., Galvani, M., Vecchia, L. L., & Maggioni, A. P. (2009) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e3283212f07 · Cited by 10
Jang, S.-W., Rho, T., Kim, D., Cho, E. J., Kwon, B., Park, H., Shin, W., Kim, J., Lee, J. M., Moon, K., et al. (2011) · Korean Circulation Journal · doi:10.4070/kcj.2011.41.10.578 · Cited by 10
Modern role for clopidogrel in management of atrial fibrillation and stroke reduction
Mäegdefessel, L. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6104 · Cited by 10
Zinn, A. P., & Feit, F. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.06.016 · Cited by 10
Menozzi, M., Rubboli, A., Manari, A., Palma, R. D., & Grilli, R. G. (2012) · Thrombosis Journal · doi:10.1186/1477-9560-10-22 · Cited by 10
Stroke Prevention in Atrial Fibrillation
Mant, J., & Edwards, D. (2010) · Drugs & Aging · doi:10.2165/11538620-000000000-00000 · Cited by 10
Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
Dzeshka, M. S., & Lip, G. Y. H. (2016) · Heart Failure Clinics · doi:10.1016/j.hfc.2015.08.021 · Cited by 11
“However, the combination of aspirin and clopidogrel still remained inferior to OAC.(71) Considering the aforementioned assertions, antiplatelet therapy as a means of stroke prophylaxis is only recommended for AF patients who are unsuitable for or with contraindications to any form of OAC (see Fig.”
BackgroundInfluentialMechanism underlying thrombus formation in cerebral infarction
Kitagawa, K., & Sakoda, S. (2009) · Rinsho Shinkeigaku · doi:10.5692/clinicalneurol.49.798 · Cited by 10
New developments in anticoagulation for atrial fibrillation
Usman, M., Notaro, L. A., Patel, H., & Ezekowitz, M. D. (2008) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-008-0030-0 · Cited by 10
Atrial fibrillation and stroke: It's not necessarily all about the rhythm
Piccini, J. P., & Daubert, J. P. (2011) · Heart Rhythm · doi:10.1016/j.hrthm.2011.05.005 · Cited by 10
Limbruno, U., Goette, A., & Caterina, R. D. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.05.024 · Cited by 10
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Sotomi, Y., Kozuma, K., Kashiwabara, K., Higuchi, Y., Andò, K., Morino, Y., Ako, J., Tanabe, K., Muramatsu, T., Nakazawa, G., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-048354 · Cited by 9
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure
Boos, C. J., Nam, M. C. Y., & Camm, A. J. (2013) · Heart Failure Reviews · doi:10.1007/s10741-013-9398-3 · Cited by 9
“0; n = 3,371) with clopidogrel (75 mg per day) plus aspirin (75–100 mg per day) in patients with NVAF [69].”
BackgroundPrevention of cardioembolic stroke in patients with atrial fibrillation
Weber, R., Diener, H., & Weimar, C. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.103 · Cited by 8
Lopez-Sendon, J. L., & Merino, J. L. (2012) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(12)70046-8 · Cited by 9
Atrial fibrillation in the elderly – Not a benign condition
Lee, G., Stub, D. A., & Ling, H. (2012) · International Emergency Nursing · doi:10.1016/j.ienj.2012.05.003 · Cited by 9
“In those with coronary artery disease who required coronary stenting and were prescribed clopidogrel, the Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of vascular events – the warfarin arm demonstrated superiority of warfarin over clopidogrel with aspirin in terms of bleeding events (Connolly e…”
BackgroundRöther, J., & Crijns, H. J. G. M. (2010) · Cerebrovascular Diseases · doi:10.1159/000319608 · Cited by 9
Clinical trials of direct thrombin and factor Xa inhibitors in atrial fibrillation
Stewart, R. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283477dbc · Cited by 9
Jackman, W. M., Stevenson, W. G., Estes, M., Richard, L., Ezekowitz, M. D., Curtis, A. B., January, C. T., Ellenbogen, K. A., & James, E. A. (2011) · Cited by 9
Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics
Kılıç, S. (2017) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2017.7886 · Cited by 9
“Approximately 60% of the patients in randomized clinical trials (RCT) have optimal TTR percentages; whereas in most observational studies and registries, only 50% of patients reach this value (7-9).”
BackgroundSaito, Y., & Kobayashi, Y. (2019) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-019-00600-1 · Cited by 9
A Watch-Type Electrocardiography Is a Reliable Tool for Detecting Paroxysmal Cardiac Arrhythmias
Kim, Y. G., Choi, J., Jung, J. S., Min, K., Choi, Y. Y., Shim, J., Son, H. S., & Kim, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123333 · Cited by 9
Sciahbasi, A., Gargiulo, G., Talarico, G. P., Cesaro, A., Zilio, F., Rosa, S. D., Talanas, G., Tebaldi, M., Andò, G., Rigattieri, S., et al. (2022) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001372 · Cited by 9
Santagata, D., Donadini, M. P., & Ageno, W. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101119 · Cited by 9
Left Atrial Appendage Closure: A Narrative Review
Nagasaka, T., & Nakamura, M. (2023) · Cardiology and Therapy · doi:10.1007/s40119-023-00337-2 · Cited by 9
“For decades, anti-coagulation with vitamin K antagonists (VKAs) has been the standard care for the prevention of thromboembolic events in patients with AF, since warfarin is proven to be more effective than aspirin and dual antiplatelet therapy in reducing cerebral events [11–13].”
BackgroundΤζιόμαλος, Κ., Giampatzis, V., Bouziana, S. D., Spanou, M., Kostaki, S., Papadopoulou, M., Dourliou, V., Sofogianni, A., Savopoulos, C. G., & Hatzitolios, A. I. (2015) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1262-y · Cited by 9
Impact of Atrial Fibrillation and Sinus Rhythm Restoration on Reticulated Platelets
Tafur, A. J., McBane, R. D., Ammash, N. M., Asirvatham, S. J., Miller, R. D., Janczak, D. T., Slusser, J. P., Grill, D. E., Whelan, S. L., & Wysokiński, W. E. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.09.013 · Cited by 9
Dabigatran in atrial fibrillation: pharmacology and clinical trials
Ezekowitz, M. D., & Nagarakanti, R. (2011) · Journal of Interventional Cardiac Electrophysiology · doi:10.1007/s10840-011-9593-x · Cited by 9
de Andrés-Nogales, F., Oyagüez, I., Nicolás, L. B., Fontcuberta, C. C., & Soto-Álvarez, J. (2014) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2014.08.003 · Cited by 9
Martín‐Yuste, V., Brugaletta, S., González, I. F., Cola, C., Alvarez-Contreras, L. R., de Antonio, M., Vicens Martí, C., García‐Picart, J., & Sabaté, M. (2011) · EuroIntervention · doi:10.4244/eijv6i7a143 · Cited by 9
Balucani, C., Barlinn, K., Živanović, Ž., Parnetti, L., Silvestrini, M., & Alexandrov, A. V. (2010) · Stroke Research and Treatment · doi:10.4061/2010/427418 · Cited by 9
Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation
Dzeshka, M. S., & Lip, G. Y. H. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.07.009 · Cited by 10
Unanswered Questions in Patients With Concurrent Atrial Fibrillation and Acute Coronary Syndrome
Ice, D. S., Shapiro, T. A., Gnall, E., & Kowey, P. R. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.11.046 · Cited by 9
Pasceri, V., Patti, G., Pristipino, C., Pelliccia, F., Irini, D., Varveri, A., Roncella, A., Sciascio, G. D., & Speciale, G. (2009) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.22380 · Cited by 9
Gattellari, M., Leung, D. Y., Ukoumunne, O. C., Zwar, N. A., Grimshaw, J., & Worthington, J. M. (2011) · Implementation Science · doi:10.1186/1748-5908-6-48 · Cited by 9
Stroke Prevention in Atrial Fibrillation
Haft, J. I. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029612458148 · Cited by 10
“Antiplatelet agents, such as aspirin and clopidogrel, are not subject to many of the issues outlined above, but they are considerably less efficacious than warfarin.(6,16) Current ACCP guidelines recommend that patients with AF who are at intermediate or high risk of stroke receive oral anticoagulants rather than aspi…”
BackgroundCardioembolic stroke: a variety of causes and current approaches to its prevention
Гераскина, Л. А. (2013) · Neurology neuropsychiatry Psychosomatics · doi:10.14412/2074-2711-2013-2457 · Cited by 9
Hirai, T., Hamada, Y., Geka, Y., Kuwana, S., Hirai, K., Ishibashi, M., Fukaya, Y., & Kimura, T. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2316-1 · Cited by 9
Clinical Profile of Atrial Fibrillation in Tertiary Hospital in Central Nepal
Dhungel, S., & Laudari, S. (2017) · Journal of Nepal Medical Association · doi:10.31729/jnma.3276 · Cited by 9
Optimal long-term antithrombotic management of atrial fibrillation: life cycle management
Pisters, R., Elvan, A., Crijns, H. J. G. M., & Hemels, M. E. W. (2018) · Netherlands Heart Journal · doi:10.1007/s12471-018-1118-0 · Cited by 9
Triple antithrombotic therapy for atrial fibrillation and coronary stents.
Shmyr, D., der Merwe, V. V., Yakiwchuk, E., Barry, A. R., & Kosar, L. (2017) · Europe PMC (PubMed Central) · Cited by 9
Acute coronary syndrome in elderly: aspects of patient management
Ryzhkova, Y. D., Kanareikina, E. V., Atabegashvili, M. R., Константинова, Е. В., & Gilyarov, M. Y. (2019) · The Clinician · doi:10.17650/1818-8338-2019-13-1-2-19-26 · Cited by 9
“В связи с тем, что ДАТ не продемонстрировала достаточную эффективность в отношении профилактики ишемических инсультов у пациентов с фибрилляцией [18], возникает необходимость назначения”
Kawakami, S., Yasuda, S., & Ogawa, H. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.03.001 · Cited by 11
Metadata
- Authors
- ‡
- Corresponding author
- ‡
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2006-06
- Volume
- 367
- Issue
- 9526
- Pages
- 1903-1912
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2159193915
- Cited by
- 1,952
- References
- 24
- Citations by year
- 2026: 20 · 2025: 22 · 2024: 33 · 2023: 44 · 2022: 44 · 2021: 68 · 2020: 68 · 2019: 82 · 2018: 92 · 2017: 87 · 2016: 107 · 2015: 118 · 2014: 134 · 2013: 155 · 2012: 208
- FWCI
- 77.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Sanofi
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- atrial fibrillation, clopidogrel, aspirin, oral anticoagulation, stroke prevention, vascular events, major bleeding, anticoagulation monitoring, clopidogrel resistance, irbesartan, antiplatelet therapy, vascular death, myocardial infarction
- MeSH terms
- Clopidogrel, Irbesartan, Aged, Anticoagulants, Aspirin, Atrial Fibrillation, Biphenyl Compounds, Drug Therapy, Combination, Humans, Platelet Aggregation Inhibitors, Risk Factors, Severity of Illness Index, Tetrazoles, Ticlopidine, International Normalized Ratio, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
